Rise in prevalence of anaphylaxis, increase in preference among patients to choose self-administration of injections, and technological advancements in autoinjectors fuel the growth of the global autoinjectors market
The global autoinjectors market size was estimated at $1.50 billion in 2019 and is expected to hit $5.73 billion by 2027, registering a CAGR of 18.1% from 2020 to 2027.
Autoinjector is a medical device, which is used to administer a particular dose of drug into the body. These devices are easy to use, are cost effective, and can be used by patients or even by untrained professionals. These devices are preferred over conventional devices as they are efficient, with improved and technologically advanced drug delivery mechanisms. Autoinjectors are used in several applications such as rheumatoid arthritis, anemia, migraine, multiple sclerosis, and other therapies.
Download Sample Report with Detailed COVID-19 Impact Analysis at @ https://www.alliedmarketresearch.com/request-for-customization/1461?reqfor=covid
- The outbreak of the pandemic has led to an increased demand for autoinjectors that can be used and monitored in the home environment.
- At the same time, although COVID-19 has brought effects on many aspects such as travel bans and quarantines, the restrictive measures have not been imposed on the healthcare industry, thereby leaving the global autoinjectors market unaffected.
The demand for autoinjectors is projected to experience substantial growth in the future, owing to the rise in anaphylaxis cases globally. The increase in R&D activities by key companies to establish new technology based autoinjectors is also anticipated to fuel the demand for autoinjectors during the forecast period. However, alternate treatment options such as general injections and tablets are likely to hinder the market growth during the forecast period. The availability of low-cost biosimilars in combination with autoinjectors at lower price due to loss of patent is projected to provide industry players with remunerative incentives.
Depending on type, the market is categorized into disposable and reusable autoinjectors. The disposable autoinjectors segment dominated the global market in 2019, and is anticipated to continue this trend during the forecast period. The key factors such as rise in prevalence of anaphylaxis and rheumatoid arthritis and further increasing patient preference for autoinjectors drives the growth of this treatment segment.
Get Free Sample Report @ https://www.alliedmarketresearch.com/request-sample/1461
On the basis of application, the market is categorized into rheumatoid arthritis, multiple sclerosis, anaphylaxis, and others. The anaphylaxis segment held a dominant position in the market, accounting for about 38.5% share of the global autoinjectors market in 2019. As per the Asthma and Allergy Foundation of America, allergic conditions are the most common health issues affecting children in the U.S. According to the European Academy of Allergy and Clinical Immunology (EAACI), allergy is the most common in Europe. In 2018, more than 150 million Europeans suffered from chronic allergies and it is expected that half of the European population would be affected by 2025. According to the Rheumatoid Arthritis Support Network, in 2018, the rheumatoid arthritis affected over 1.3 million American and as much as 1% of the global population. Furthermore, rise in occurrences of rheumatoid arthritis to drive the demand for autoinjectors.
By end user, the market is categorized into home care settings and hospitals & clinics. The home care settings segment held a dominant portion in the market, accounting for about 62.8% share of the global autoinjectors market in 2019.Most autoinjectors are used for self-administration of drugs and re less frequently recommended for hospital use to further avoid rise of infections.
North America accounted for the largest share in the global autoinjectors market. Asia-Pacific is expected to witness highest growth rate for throughout the forecast period. Rise in cases of anaphylaxis; rheumatoid arthritis; and other diseases such as anemia and migraine; and further increase in technological advancements by companies are anticipated to drive the overall autoinjectors market growth.
For Purchase Enquiry @ https://www.alliedmarketresearch.com/purchase-enquiry/1461
The market report provides an in-depth analysis of the major market players such as
Amgen, Antares Pharma, Becton Dickinson and Company, Eli Lilly and Company, Johnson and Johnson, Mylan N.V., Novartis AG, SHL Medical, Teva Pharmaceutical Industries Ltd and Ypsomed AG.
Scope of The Report:
|Market size available for years||2019-2027|
|Base year considered||2019|
|Forecast units||Value (USD)|
|Segments covered||Type, Application, and End user|
|Geographies covered||North America, Europe, Asia-Pacific, LAMEA|
Similar Report with Detailed COVID-19 Impact Analysis:
Smart Syringe Market by Product (Auto Disable Syringes, Active Safety Syringes and Passive Safety Syringes), Application (Drug Delivery, Vaccination, and Blood Specimen Collection), Age Group (Pediatrics and Adults), and End User (Hospitals & HMOs, Diabetic Patients, Family Practices, Psychiatrics, and Others): Global Opportunity Analysis and Industry Forecast, 2020–2027
Intravenous (IV) Ibuprofen Market by Indication (Pain/Inflammatory, Fever) and Age Group (Pediatrics, Adults) – Global Opportunity Analysis and Industry Forecast, 2015 – 2022
Malaysia Intravenous Immunoglobulin (IVIG) Market by Product Types (IgG, IgA, IgM, IgE and IgD), Application (Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy, Immunodeficiency Diseases, Myasthenia Gravis, Multifocal Motor Neuropathy, Primary Immune Thrombocytopenic Purpura, Inflammatory Myopathies, Specific Antibody Deficiency, Guillain-Barre Syndrome, Kawasaki Disease, Secondary Immune Deficiency, and Other Applications), Mode of Delivery (Intravenous, Intramuscular, and Subcutaneous), and Concentration (5%, 10%, and Other Concentration): Opportunity Analysis and Industry Forecast, 2014-2022
Self-Injections Market by Type [Devices (Needle-Free Injectors, Auto Injectors, Pen Injectors, Wearable Injectors), and Formulations], Dosage Form (Single Dose, and Multi-Dose), Therapeutic Application (Autoimmune Diseases, Hormonal Disorders, Oncology, Orphan Diseases, Pain Management, and Respiratory Therapy)], by Route of Administration (Skin, Circulatory/Musculoskeletal, Organs, and Central Nervous System), By End-User (Patient, Physicians, and Home Care Settings), By Distribution Channel (Hospital Pharmacies, Private Clinics, Chemist, and Online Pharmacies) – Global Opportunity Analysis and Industry Forecast, 2020-2027